Canadian HIV & Viral Hepatitis Pharmacists Network (CHAP) Activities

Group Communication

Use this email for group communication and clinical sharing sessions:

chap-HIV@googlegroups.com

This list is open to the general membership of CHAP, and includes pharmacists who are actively interested in HIV pharmacology and/or practice. This group is a restricted list, which means that new members are added by the moderator (Chair). If there are new members who would like to join, they should e-mail the Chair at: chap@hivclinic.ca with a request and a brief bio sketch.

CHAP Chats

• October 25, 2024: Fall Respiratory Vaccine Update (T. Ramsey) (passcode n7c*8pWR)
• November 2023: Hepatitis C: it can still be challenging (J. Feld)
• March 2023: Infant feeding in HIV (S. Khan)
• June 2022: A pharmacist’s guide to the use of dual-therapy regimens for HIV infection (CCCEP#: 1329-2022-3369-I-P) (S. Campbell)
• December 2021: Antiretroviral resistance: cases (S. Shafran)
• September 2021: COVID vaccines and variants (A. Sharkawy)
• June 2021: HIV and aging (S. Walmsley)
• May 2021: HIV and pediatrics (J. Brophy)
• April 2021: HCV update (D. Martel) – HCV CHAP 2021
• March 2021: What to do about M184V? (C. Brumme); Resistance case (L. Akagi)
• February 2021: Antiretrovirals in Pregnancy (K. Tulloch); Overview of Women-Centred HIV Care Toolkits (M. Loutfy & M. Ndung’u)

CHAP National Clinical Observership Program

This program supports 3-4 observerships per year, based on available funds. Canadian CHAP members may apply for a 2-4 day observership in order to enhance clinical skills and expertise through clinical shadowing/teaching with an experienced HIV pharmacy practitioner at an established practice site. This program is open to new pharmacists entering the area of HIV practice, as well as experienced CHAP members who wish to gain experience in a new clinical area/skill/program. Logistical costs of the program are supported via Sponsorship with Gilead Sciences Canada. Observership applicants and members of the Observership Working Group do not receive any honoraria/consulting fees for their time developing/administering this project.

• Terms of Reference
• Application Process

CHAP Endorsements

CHAP endorsement indicates overall support for an initiative or guideline that is evidence-based, reasonable, and does not contradict CHAP’s mission and values. CHAP is proud to endorse the following guidelines and recommendations:

• Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1. Sherman E et al. Pharmacother 2024;44:488-493.
• Canadian Pediatric & Perinatal HIV/AIDS Research Group consensus recommendations for infant feeding in the HIV context. Khan S et al. J Assoc Med Microbiol Infect Dis Can 2023;8:7-17.
• Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. Tan DHS et al. CMAJ 2017;189:E1448-58.
• ASHP guidelines on pharmacist involvement in HIV care. Schafer JJ et al. Am J Health-Syst Pharm 2016;73:468-94.

Professional Advocacy

In 2000, CHAP, along with the Society of Infectious Diseases Pharmacists, the American Society of Health-Systems Pharmacists, and the American College of Clinical Pharmacy, submitted a formal letter of protest to the Retrovirus Conference planning committee regarding the selective exclusion of pharmacist registrants to the Retrovirus conference. These collaborative efforts resulted in subsequent modification of pharmacist registration criteria for this prestigious annual meeting.